Science Pool

Just – Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies

Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle, Washington-based subsidiary, Just – Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (“mAbs”) for use in the development of a treatment and/or prophylaxis for COVID-19.
Read More